Drug Combination Details
| General Information of the Combination (ID: C10466) | |||||
|---|---|---|---|---|---|
| Name | Apicidin NP Info | + | Gemcitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Capan-1 | CVCL_0237 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. Anticancer Res. 2014 Oct;34(10):5269-76. | |||
